# DOLUTEGRAVIR;LAMIVUDINE;TENOFOVIR ALAFENAMIDE
> **NDA215187** · New Drug Application · Sponsor: LUPIN PHARMS · Approved 2023-07-18
## Drug
- **FDA Application Number:** NDA215187
- **Application type:** New Drug Application
- **Brand name:** DOLUTEGRAVIR;LAMIVUDINE;TENOFOVIR ALAFENAMIDE
- **Generic name:** Dolutegravir
- **Active ingredients:** DOLUTEGRAVIR; LAMIVUDINE; TENOFOVIR ALAFENAMIDE
- **Dosage form:** TABLET
- **Route:** ORAL
- **Marketing status:** None (Tentative Approval)
- **Sponsor:** LUPIN PHARMS
- **First approval:** 2023-07-18
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215187)
---
*AI Analytics · CC0 1.0*